94% reduction in progression from pre diabetes to type 2 diabetes with tirzepatide.** **Based on a three-year clinical trial study (176-week treatment period) sponsored by Eli Lilly and Company, weekly injections of tirzepatide significantly reduced the risk of progression to type 2 diabetes by 94% in adults with prediabetes who were overweight or obese compared to placebo
In a phase II trial, obese participants who were administered retatrutide lost an average of 24.2 percent of their body weight over a 48-week period, Wired noted, which is more than what other drugs have achieved in nearly twice the amount of time
If youre ready to delve into a comprehensive analysis, this article is your guide to optimizing weight loss treatment strategies
The most common side effects include: Gastrointestinal issues: Nausea, vomiting, diarrhea, and constipation are common side effects of semaglutide, especially during the initial stages of treatment
Then you say, Im not going to go over 5 pounds over that